134 related articles for article (PubMed ID: 26530405)
1. Detection of neuroendocrine tumors using promoter-specific secreted Gaussia luciferase.
Tseng AW; Akerstrom V; Chen C; Breslin MB; Lan MS
Int J Oncol; 2016 Jan; 48(1):173-80. PubMed ID: 26530405
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific promoter-driven adenoviral therapy for insulinoma.
Tseng AW; Chen C; Breslin MB; Lan MS
Cell Oncol (Dordr); 2016 Jun; 39(3):279-86. PubMed ID: 26902080
[TBL] [Abstract][Full Text] [Related]
3. Modifications to the INSM1 promoter to preserve specificity and activity for use in adenoviral gene therapy of neuroendocrine carcinomas.
Akerstrom V; Chen C; Lan MS; Breslin MB
Cancer Gene Ther; 2012 Dec; 19(12):828-38. PubMed ID: 23079673
[TBL] [Abstract][Full Text] [Related]
4. INSM1 promoter-driven adenoviral herpes simplex virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors.
Wang HW; Breslin MB; Chen C; Akerstrom V; Zhong Q; Lan MS
Hum Gene Ther; 2009 Nov; 20(11):1308-18. PubMed ID: 19604042
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral insulinoma-associated protein 1 promoter-driven suicide gene therapy with enhanced selectivity for treatment of neuroendocrine cancers.
Akerstrom V; Chen C; Lan MS; Breslin MB
Ochsner J; 2013; 13(1):91-9. PubMed ID: 23533081
[TBL] [Abstract][Full Text] [Related]
6. The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer.
Pedersen N; Pedersen MW; Lan MS; Breslin MB; Poulsen HS
Cancer Gene Ther; 2006 Apr; 13(4):375-84. PubMed ID: 16052225
[TBL] [Abstract][Full Text] [Related]
7. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
[TBL] [Abstract][Full Text] [Related]
8. Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer.
Chen C; Breslin MB; Lan MS
Cell Signal; 2018 Jun; 46():83-91. PubMed ID: 29501727
[TBL] [Abstract][Full Text] [Related]
9. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
10. Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells.
Michaelsen SR; Christensen CL; Sehested M; Cramer F; Poulsen TT; Patterson AV; Poulsen HS
J Gene Med; 2012 Jul; 14(7):445-58. PubMed ID: 22576955
[TBL] [Abstract][Full Text] [Related]
11. INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms.
Rosenbaum JN; Guo Z; Baus RM; Werner H; Rehrauer WM; Lloyd RV
Am J Clin Pathol; 2015 Oct; 144(4):579-91. PubMed ID: 26386079
[TBL] [Abstract][Full Text] [Related]
12. Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer.
Fujino K; Motooka Y; Hassan WA; Ali Abdalla MO; Sato Y; Kudoh S; Hasegawa K; Niimori-Kita K; Kobayashi H; Kubota I; Wakimoto J; Suzuki M; Ito T
Am J Pathol; 2015 Dec; 185(12):3164-77. PubMed ID: 26482608
[TBL] [Abstract][Full Text] [Related]
13. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
14. INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors.
Rooper LM; Bishop JA; Westra WH
Am J Surg Pathol; 2018 May; 42(5):665-671. PubMed ID: 29438167
[TBL] [Abstract][Full Text] [Related]
15. A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases.
Kuji S; Watanabe R; Sato Y; Iwata T; Hirashima Y; Takekuma M; Ito I; Abe M; Nagashio R; Omae K; Aoki D; Kameya T
Gynecol Oncol; 2017 Feb; 144(2):384-390. PubMed ID: 27908529
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
17. Insulinoma-Associated-1: From Neuroendocrine Tumor Marker to Cancer Therapeutics.
Chen C; Notkins AL; Lan MS
Mol Cancer Res; 2019 Aug; 17(8):1597-1604. PubMed ID: 31113827
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
Zhu ZB; Makhija SK; Lu B; Wang M; Kaliberova L; Liu B; Rivera AA; Nettelbeck DM; Mahasreshti PJ; Leath CA; Barker S; Yamaoto M; Li F; Alvarez RD; Curiel DT
Cancer Gene Ther; 2004 Apr; 11(4):256-62. PubMed ID: 15017380
[TBL] [Abstract][Full Text] [Related]
19. Insulinoma-associated protein 1 immunostaining on cytology specimens: an institutional experience.
Rodriguez EF; Fite JJ; Chowsilpa S; Maleki Z
Hum Pathol; 2019 Mar; 85():128-135. PubMed ID: 30502379
[TBL] [Abstract][Full Text] [Related]
20. The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells.
Shi CX; Long MA; Liu L; Graham FL; Gauldie J; Hitt MM
Mol Ther; 2004 Oct; 10(4):758-67. PubMed ID: 15451460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
